This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/pharmgkb/
n27http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/pdb/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/pubchem-substance/
n16http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/national-drug-code-directory/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00753/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00753
rdf:type
n3:Drug
n3:description
A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem]
n3:dosage
n26:271B582C-363D-11E5-9242-09173F13E4C5 n26:271B582D-363D-11E5-9242-09173F13E4C5 n26:271B582E-363D-11E5-9242-09173F13E4C5 n26:271B582B-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For induction and maintenance of general anesthesia.
n3:manufacturer
n27:271B5827-363D-11E5-9242-09173F13E4C5 n27:271B5828-363D-11E5-9242-09173F13E4C5 n27:271B5825-363D-11E5-9242-09173F13E4C5 n27:271B5826-363D-11E5-9242-09173F13E4C5 n27:271B5829-363D-11E5-9242-09173F13E4C5 n27:271B5824-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00753 n16:DB00753
dcterms:title
Isoflurane
adms:identifier
n9:ICF n10:PA450106 n11:D00545 n12:0409-3292-01 n13:3763 n14:46505880 n15:6015 n17:C07518 n18:3631 n20:DB00753 n23:Isoflurane
n3:mechanismOfAction
Isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Isoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Isoflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.
n3:packager
n27:271B581C-363D-11E5-9242-09173F13E4C5 n27:271B5823-363D-11E5-9242-09173F13E4C5 n27:271B5821-363D-11E5-9242-09173F13E4C5 n27:271B5822-363D-11E5-9242-09173F13E4C5 n27:271B581F-363D-11E5-9242-09173F13E4C5 n27:271B5820-363D-11E5-9242-09173F13E4C5 n27:271B581D-363D-11E5-9242-09173F13E4C5 n27:271B581E-363D-11E5-9242-09173F13E4C5
n3:synonym
Forene 1-chloro-2,2,2-Trifluoroethyl difluoromethyl ether Isofluranum Isoflurano Isoflurane Forane Aerrane Ethane
n3:toxicity
LC50=15300 ppm/3 hrs (inhalation by rat)
n24:hasAHFSCode
n25:28-04-00 n25:28-04-92
n3:synthesisReference
Leonid A. Rozov, Fernando Quiroz, Gerald G. Vernice, "Preparation of isoflurane." U.S. Patent US5416244, issued March, 1973.
foaf:page
n22:isoflurane.htm
n3:IUPAC-Name
n4:271B5833-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5839-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5838-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5835-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5836-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5837-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5831-363D-11E5-9242-09173F13E4C5 n4:271B5848-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B582F-363D-11E5-9242-09173F13E4C5 n4:271B5832-363D-11E5-9242-09173F13E4C5 n4:271B584B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5830-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n28:N01AB06
n3:H-Bond-Acceptor-Count
n4:271B583F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5840-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B583A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B583B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B583D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B583C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B583E-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
26675-46-7
n3:category
n3:containedIn
n19:271B582A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5844-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B584A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5846-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5847-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5849-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5843-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5842-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5845-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5834-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5841-363D-11E5-9242-09173F13E4C5